Urokinase plasminogen activator: A prognostic marker in multiple types of cancer

Journal of Surgical Oncology

Volumn 71, Issue 2, 1999, Pages 130-135

  Duffy, Michael J ^a,b   Maguire, Teresa M ^a,b   Mcdermott, Enda W ^a,b   O'Higgins, Niall ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cancer; Plasminogen activator; Prognosis; Urokinase

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADENOCARCINOMA; ADJUVANT THERAPY; BREAST CANCER; CANCER; COLORECTAL CANCER; ESOPHAGUS CANCER; HUMAN; LYMPH NODE METASTASIS; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR VOLUME;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LYMPH NODES; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033026635     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9     Document Type: Review

References (59)

1. Zetter B: Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-414.
2. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-155.
3. Duffy MJ: The biochemistry of metastasis. Adv Clin Chem 1996; 32:135-166.
4. Reuning U, Magdolen V, Wilhelm O, et al.: Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998;13:893-906.
5. Andreasen PA, Kjoller L, Christiansen L, et al.: The urokinase-type plasminogen activation system in cancer metastasis. Int J Cancer 1997;72:1-22.
6. Lijnen HR, Silence J, Lemmens G, et al.: Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost 1998;79;1171-1176.
7. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992;267: 10931-10934.
8. Duffy MJ: Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 1987;23:583-589.
9. Duffy MJ, O'Grady P, Devaney D, et al.: Urokinase-plasminogen activator, a marker for aggressive breast cancer. Preliminary report. Cancer 1988;62:531-533.
10. Duffy MJ, Reilly D, O'Sullivan C, et al.: Urokinase plasminogen activator and prognosis in breast cancer. Lancet 1990;335:109.
11. Janicke F, Schmitt M, Ulm K, et al.: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; ii:1049.
12. Schmitt M, Janicke F, Graeff H: Tumor-associated fibrinolysis: The prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1990;1:695-702.
13. Spyratos F, Martin P-M, Hacene K, et al.: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992;84:1266-1272.
14. Cook D, Mahmoud-Alexandroni N, Gaffney PJ, et al.: Plasminogen activators are powerful indicators of prognosis in breast cancer. Br J Surg 1991;78:1495.
15. Foekens J, Schmitt M, Pache L, et al.: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-6105.
16. Bouchet C, Spyratos F, Martin P-M, et al.: Prognostic role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994;69:398-405.
17. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al.: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinoma are associated with poor prognosis. Cancer Res 1993;53:2513-2521.
18. Ferno M, Bendahl PO, Borg A, et al.: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer: analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996;32A:793-801.
19. Umeda T, Eguchi Y, Okino K, et al.: Cellular localisation of urokinase-type plasminogen activator, its inhibitors and their mRNA in breast cancer tissue. J Pathol 1997;183:388-397.
20. Shiba E, Kim SJ, Taguchi T, et al.: A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. J Cancer Res Clin Oncol 1997;123: 555-559.
21. Knoop A, Andreasen PA, Anderson JA, et al.: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998; 77:932-940.
22. Peyrat J-P, Vanlemmens L, Fournier J, et al.: Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancer. Clin Cancer Res 1998;4:189-196.
23. Grondahl-Hansen J, Hilsenbeck S, Christensen IJ, et al.: Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:153-163
24. Broet P, Spyratos F, Romain S, et al.: Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: A multicenter study. Br J Cancer 1999;(in press).
25. Kim SJ, Shiba E, Kobayashi T, et al.: Prognostic impact of urokinase-type plasminogen activator (uPA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998;4: 177-182.
26. Bouchet C, Spyratos F, Hacene K, et al.: Prognostic value of urokinase plasminogen activator in primary breast carcinomas: Comparison of 2 immunoassay methods. Br J Cancer 1998;77: 1495-1501.
27. Tetu B, Brisson J, Lapointe H. Prognostic significance of stromelysin 3, gelatinase A and urokinase expression in breast cancer. Hum Pathol 1998;29:979-985.
28. Eppenberger U, Kueng W, Schlaeppi J-M, et al.: Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998;16:3129-3136.
29. Kute TE, Grondahl-Hansen J, Shao S-M, et al.: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols define a group of node-negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998;47:9-16.
30. Duffy MJ, Duggan C, Maguire T, et al.: Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enz Protein 1996;49:85-93.
31. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-618.
32. Duffy MJ, Reilly D, O'Sullivan C, et al.: Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-6829.
33. Janicke F, Schmitt M, Pache L, et al.: Urokinase plasminogen activator (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
34. Maguire TM, Shering SG, Duggan C, et al.: High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers 1998;13:139-144.
35. Duffy MJ, Reilly D, McDermott E, et al. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994;74:2276-2280.
36. Duffy MJ, Duggan C, Mulcahy H, et al.: Urokinase plasminogen activator: A prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 1998;44:1177-1183.
37. Foekens J, Look MP, Peters HA, et al.: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995;87:751-756.
38. Berns EMJJ, Klijn JGM, van Putten WLJ, et al.: p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol 1998;16:121-127.
39. Schmitt M, Harbeck N, Thomssen C, et al.: Clinical impact of the plasminogen activator system in tumor invasion and metastasis. Thromb Haemost 1997;78:285-296.
40. Ganesh S, Sier CFM, Griffioen G, et al.: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-4071.
41. Mulcahy H, Duffy MJ, Gibbons D, et al.: Urokinase-type plasminogen activator and outcome in Duke's B colorectal cancer. Lancet 1994;344:583-584.
42. Sato T, Nishimura G, Yonemura Y, et al.: Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 1995;52:347-352.
43. Skelly M, Troy A, Duffy MJ, et al.: Urokinase-type plasminogen activator in colorectal cancer: Relationship with clinicopathological features and patient outcome. Clin Cancer Res 1997;3:1837-1840.
44. Kim SJ, Shiba E, Tsukamoto F, et al.: The expression of urokinase-type plasminogen activator is a novel prognostic factor in Dukes B and C colorectal cancer. Oncol Rep 1998;5:431-435.
45. Nekarda H, Schmitt M, Ulm K, et al.: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-2907.
46. Heiss M, Babic R, Allgayer H, et al.: Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995;13:2084-2093.
47. Cho JY, Chung HC, Roh JK, et al.: High levels of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric cancer. Cancer 1997;79:878-883.
48. Nekarda H, Schlegel P, Schmitt M, et al.: Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998;4:1755-1763.
49. Torzewski M, Sarbia M, Verreet P, et al.: Prognostic significance of urokinase-type plasminogen activator in squamous cell carcinoma of the esophagus. Clin Cancer Res 1997;3:2263-2268.
50. Hasui Y, Marutsuka K, Suzumiya J, et al.: The content of urokinase-type plasminogen activator as a prognostic factor in bladder cancer. Int J Cancer 1992;50:871-873.
51. Oka T, Ishida T, Nishino T, et al.: Immunochemical evidence of urokinase plasminogen activator in primary and metastatic tumors of pulmonary carcinoma. Cancer Res 1991;51:3522-3525.
52. Kobayashi H, Fujishiro S, Terao T: Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994;54:6539-6548.
53. Kuhn W, Schmalfeldt B, Reuning U, et al.: Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999;79:1746-1751.
54. Hofmann R, Lehmer A, Buresch M, et al.: Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-492.
55. De Petro G, Tavian D, Copeta A, et al.: Expression of urokinase-type plasminogen activator (uPA), uPA receptor and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 1998;58:2234-2239.
56. Cantero D, Friess H, Deflorin J, et al.: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997;75:388-395.
57. Hsu DW, Efird J, Hedley-Whyte ET: Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995; 147:114-123.
58. Choong PFM, Ferno M, Akerman M, et al.: Urokinase plasminogen activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 1996;69:268-272.
59. Duggan C, Maguire T, McDermott E, et al.: Urokinase plasminogen activator and urokinase plasminogen receptor in breast cancer. Int J Cancer 1995;61:597-600.